# The Reasoning Engine

Sarkome's core technology is a **Reasoning Engine**—a system that transforms the challenge of therapeutic discovery from guesswork into systematic causal inference.

## The Challenge of Cancer Drug Discovery

Traditional drug discovery approaches face fundamental limitations:

### High-Throughput Screening (HTS)
- Screens thousands of compounds hoping for statistical hits
- Works for simple targets with clear binding pockets
- **Fails for**: Complex targets, transcription factors, fusion proteins

### Fragment-Based Drug Discovery (FBDD)
- Builds drugs from small molecular fragments
- Requires well-defined structural targets
- **Fails for**: Intrinsically disordered proteins, protein-protein interfaces

### AI/ML Predictions
- Pattern-matches against historical data
- Generates predictions without causal understanding
- **Fails for**: Novel mechanisms, sparse data domains, rare diseases

## Sarkome's Approach: Causal Inference

Instead of statistical pattern matching, Sarkome's Reasoning Engine performs **deterministic causal inference**:

### What This Means

Rather than asking *"What compounds correlate with positive outcomes in similar diseases?"*

The engine asks *"What biological mechanism causes this disease, and what intervention would causally reverse it?"*

### The Difference

| Statistical Approach | Causal Approach |
|---------------------|-----------------|
| "These compounds worked in similar cancers" | "This pathway drives the tumor; blocking it at this point should arrest growth" |
| Pattern matching on historical data | Mechanistic reasoning from first principles |
| Correlation-based predictions | Causation-based hypotheses |
| Black-box recommendations | Explainable therapeutic logic |

## How the Reasoning Engine Works

### 1. Semantic Firewall

Before any reasoning begins, the engine validates inputs:

- **Entity Resolution**: Maps mentions to canonical identifiers (genes, proteins, diseases)
- **Relationship Validation**: Confirms that proposed connections exist in the knowledge graph
- **Contradiction Detection**: Flags claims that conflict with established biology

This prevents the garbage-in-garbage-out problem that plagues other AI systems.

### 2. Multi-Hop Causal Chains

The engine constructs causal chains through the knowledge graph:

```
Mutation X → Overexpression of Protein A → Activation of Pathway B → 
Suppression of Apoptosis → Tumor Survival
```

Each arrow represents a validated biological relationship. The engine can then reason:

*"If we inhibit Protein A, we disrupt the chain at step 2, potentially restoring apoptosis."*

### 3. Mechanism Validation

Proposed mechanisms are validated against multiple evidence types:

- **Structural feasibility**: Can the proposed intervention physically bind to the target?
- **Pathway coherence**: Are the downstream effects consistent with known biology?
- **Clinical precedent**: Have similar mechanisms succeeded in related contexts?

### 4. Negative Space Analysis

The engine explicitly considers what *hasn't* worked:

- Which drugs targeting this pathway have failed?
- What were the failure modes?
- What alternative approaches haven't been tried?

This prevents repetition of known dead ends.

## Specialized Capabilities

### Fusion Oncoprotein Analysis

Fusion proteins—aberrant combinations of two genes—drive many rare cancers. Traditional methods struggle because:

- The fusion creates novel binding surfaces
- No historical drug data exists
- The fusion may be intrinsically disordered

Sarkome's engine uses structural predictions and mechanistic reasoning to generate hypotheses for these "undruggable" targets.

### Rare Disease Optimization

Rare diseases suffer from sparse data—few patients, few studies, few drug trials. The engine compensates by:

- Transferring insights from mechanistically similar diseases
- Identifying shared pathway vulnerabilities
- Synthesizing evidence from preclinical and off-label sources

### Resistance Mechanism Prediction

Before a drug reaches clinical trials, the engine predicts:

- Likely resistance mutations
- Alternative pathway activations
- Combination strategies to prevent resistance

## Output: Therapeutic Hypotheses

The Reasoning Engine produces structured therapeutic hypotheses:

### Components

1. **Target**: The specific protein, pathway, or mechanism to intervene on
2. **Mechanism**: How the intervention would causally affect cancer biology
3. **Intervention Strategy**: Drug class, modality, or combination approach
4. **Evidence Strength**: Confidence level based on supporting data
5. **Validation Path**: Recommended experiments to test the hypothesis
6. **Risk Factors**: Potential failure modes and how to monitor for them

### Example Output

```
HYPOTHESIS: Target CDK4/6 in combination with MEK inhibition for 
KRAS-mutant pancreatic cancer with CDKN2A loss

MECHANISM: CDKN2A loss removes cell cycle checkpoint → CDK4/6 
inhibition restores G1 arrest → Combined with MEK inhibition to 
block alternative survival pathway

EVIDENCE STRENGTH: Moderate (preclinical validation, Phase I data 
in other KRAS-driven tumors)

VALIDATION PATH: 
1. Confirm CDKN2A status in target patient population
2. Evaluate combination synergy in organoid models
3. Monitor for RB1 loss as resistance mechanism

CONFIDENCE: 72%
SOURCES: [citations...]
```

## Integration with Platform

The Reasoning Engine powers Sarkome's user-facing capabilities:

- **Query Interface**: Natural language questions trigger engine reasoning
- **Knowledge Graph**: Visualization of causal chains the engine constructs
- **Hypothesis Reports**: Structured outputs researchers can act on

---

**Experience the Reasoning Engine**: [Try the Platform](/platform)
